Trial · NCT01568866
Results by group28
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 28
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Progression-free Survival | Bortezomib + DEX | 9.4 | 95% Confidence Interval 8.4 to 10.4 | months | |
| Progression-free Survival | Carfilzomib + DEX | 18.7 | 95% Confidence Interval 15.6 to NA | months | |
| Overall Survival | Bortezomib + DEX | 40.0 | 95% Confidence Interval 32.6 to 42.3 | months | |
| Overall Survival | Carfilzomib + DEX | 47.6 | 95% Confidence Interval 42.5 to NA | months | |
| Overall Response | Bortezomib + DEX | 62.6 | 95% Confidence Interval 58.0 to 67.0 | percentage of participants | |
| Overall Response | Carfilzomib + DEX | 76.9 | 95% Confidence Interval 72.8 to 80.7 | percentage of participants | |
| Duration of Response | Bortezomib + DEX | 10.4 | 95% Confidence Interval 9.3 to 13.8 | months | |
| Duration of Response | Carfilzomib + DEX | 21.3 | 95% Confidence Interval 21.3 to NA | months | |
| Percentage of Participants With ≥ Grade 2 Peripheral Neuropathy | Bortezomib + DEX | 32.0 | 95% Confidence Interval 27.7 to 36.3 | percentage of participants | |
| Percentage of Participants With ≥ Grade 2 Peripheral Neuropathy | Carfilzomib + DEX | 6.0 | 95% Confidence Interval 3.9 to 8.2 | percentage of participants | |
| Percentage of Participants With a Significant Reduction in Left Ventricular Ejection Fraction (LVEF) | Bortezomib + DEX | 2.6 | percentage of participants | ||
| Percentage of Participants With a Significant Reduction in Left Ventricular Ejection Fraction (LVEF) | Carfilzomib + DEX | 0.0 | percentage of participants | ||
| Change From Baseline in Right Ventricular Fractional Area Change (FAC) | Bortezomib + DEX | Week 12 (n=40, 40) | -0.7 | Standard Deviation 5.00 | percent fractional area change |
| Change From Baseline in Right Ventricular Fractional Area Change (FAC) | Carfilzomib + DEX | Week 12 (n=40, 40) | -1.1 | Standard Deviation 5.36 | percent fractional area change |
| Change From Baseline in Right Ventricular Fractional Area Change (FAC) | Bortezomib + DEX | Week 24 (n=26, 31) | 0.7 | Standard Deviation 6.10 | percent fractional area change |
| Change From Baseline in Right Ventricular Fractional Area Change (FAC) | Carfilzomib + DEX | Week 24 (n=26, 31) | -1.0 | Standard Deviation 5.03 | percent fractional area change |
| Change From Baseline in Right Ventricular Fractional Area Change (FAC) | Bortezomib + DEX | Week 36 (n=15, 18) | -0.5 | Standard Deviation 7.27 | percent fractional area change |
| Change From Baseline in Right Ventricular Fractional Area Change (FAC) | Carfilzomib + DEX | Week 36 (n=15, 18) | -0.5 | Standard Deviation 6.38 | percent fractional area change |
| Change From Baseline in Right Ventricular Fractional Area Change (FAC) | Bortezomib + DEX | End of Treatment (n=23, 18) | 0.4 | Standard Deviation 4.73 | percent fractional area change |
| Change From Baseline in Right Ventricular Fractional Area Change (FAC) | Carfilzomib + DEX | End of Treatment (n=23, 18) | -1.9 | Standard Deviation 5.47 | percent fractional area change |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01568866/results